Business
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives
Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine
About this update from Reviva Pharmaceuticals Holdings, Inc.
[{"type":"text","content":"Brilaroxazine, a novel serotonin-dopamine modulator with multifaceted activities has the potential to treat idiopathic pulmonary fibrosis (IPF) Brilaroxazine improved survival and lung function, and reduced lung fibrosis and inflammation in a bleomycin-induced rodent model of IPF U.S. FDA has granted Orphan Drug Designation to brilaroxazine for IPF indication CUPERTINO, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, has presented preclinical data on the novel serotonin-dopamine modulator brilaroxazine in idiopathic pulmonary fibrosis (IPF) at the 2023 American Thoracic Society (ATS) International Conference which took place in Washington, DC, USA, May 19-24, 2023. The Company also announced acceptance of this data for publication in Medical Research Archives. The ATS poster and online publication will be available at revivapharma.com/publications. “The improvement in survival and lung function, coupled with significant reduction in fibrosis and proinflammatory cytokines in the bleomycin-induced rodent model of IPF reinforces the multifaceted action of brilaroxazine,” said Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva. “This preclinical evaluation in IPF provides proof-of-concept support for the potential of brilaroxazine to treat pulmonary fibrosis and inflammation stemming from underlying dysfunction in serotonin signaling in the lung. Brilaroxazine has already received Orphan Drug Designation by the U.S. FDA for IPF.” Idiopathic pulmonary fibrosis (IPF) is a debilitating lung disease involving chronic inflammation and progressive alveolar fibrosis that leads to destroyed architecture, reduced capacity, impaired oxygenation, and declined function. While two treatments − Nintedanib (Ofev®) and Pirfenidone (Esbriet®) – have been approved by the Food and Drug Administration (FDA), the ability to address unmet needs is still limited by inadequate improvements in lung function decline, disease progression and survival rates. Most IPF patients suffer from chronic mental illness (e.g. depression, psychosis). Serotonin (5-HT) signaling plays a key role, via 5-HT2...